Novartis AG (NYSE:NVS) – Stock analysts at Jefferies Group issued their Q1 2017 EPS estimates for Novartis AG in a report released on Tuesday. Jefferies Group analyst J. Holford expects that the company will post earnings per share of $1.08 for the quarter. Jefferies Group also issued estimates for Novartis AG’s FY2018 earnings at $5.35 EPS, FY2019 earnings at $6.17 EPS and FY2020 earnings at $6.90 EPS.

Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Wednesday, January 25th. The company reported $1.12 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.12. Novartis AG had a return on equity of 15.37% and a net margin of 13.80%. The company earned $12.32 billion during the quarter, compared to analysts’ expectations of $12.44 billion. During the same period last year, the firm earned $1.14 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis.

TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/04/20/novartis-ag-forecasted-to-earn-q1-2017-earnings-of-1-08-per-share-nvs.html.

Earnings History and Estimates for Novartis AG (NYSE:NVS)

A number of other equities research analysts also recently commented on the company. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis AG in a research report on Tuesday. Vetr downgraded Novartis AG from a “strong-buy” rating to a “buy” rating and set a $78.32 price objective for the company. in a research report on Thursday, April 6th. Barclays PLC initiated coverage on Novartis AG in a research report on Tuesday, March 7th. They set an “underweight” rating for the company. Societe Generale upgraded Novartis AG from a “hold” rating to a “buy” rating and increased their price objective for the company from $73.82 to $74.37 in a research report on Tuesday, March 7th. Finally, Deutsche Bank AG reiterated a “neutral” rating on shares of Novartis AG in a research report on Monday, January 9th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $83.12.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/04/20/novartis-ag-forecasted-to-earn-q1-2017-earnings-of-1-08-per-share-nvs.html

Shares of Novartis AG (NYSE:NVS) opened at 72.74 on Thursday. The firm has a market capitalization of $172.69 billion, a PE ratio of 25.98 and a beta of 0.73. The firm’s 50-day moving average price is $74.56 and its 200-day moving average price is $73.40. Novartis AG has a 52-week low of $66.93 and a 52-week high of $83.58.

Hedge funds have recently made changes to their positions in the stock. Howe & Rusling Inc. increased its stake in shares of Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock valued at $100,000 after buying an additional 882 shares during the period. Sowell Financial Services LLC purchased a new stake in shares of Novartis AG during the fourth quarter valued at about $116,000. Zions Bancorporation increased its stake in shares of Novartis AG by 21.0% in the fourth quarter. Zions Bancorporation now owns 1,656 shares of the company’s stock valued at $120,000 after buying an additional 287 shares during the period. Mosaic Family Wealth LLC increased its stake in shares of Novartis AG by 11.2% in the third quarter. Mosaic Family Wealth LLC now owns 1,886 shares of the company’s stock valued at $149,000 after buying an additional 190 shares during the period. Finally, Seven Eight Capital LP purchased a new stake in shares of Novartis AG during the fourth quarter valued at about $150,000. 9.82% of the stock is currently owned by institutional investors.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

5 Day Chart for NYSE:NVS

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.